UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug

• UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

• UBX1325 treatment generally maintained visual acuity for six months, with most patients not requiring anti-VEGF rescue.

• Patients in the every 8-week Rengeron Pharmaceuticals Inc (NASDAQ: REGN) Eylea (aflibercept) arm had an early and unexpected gain of 3.5 letters at week 2, which was mainly maintained for the duration of the study.

• The study did not meet the non-inferiority threshold compared to aflibercept through 24 weeks.

• The ENVISION study did not meet the non-inferiority margin of -4.5 letters compared to aflibercept with an 85% confidence interval.

• UBX1325 demonstrated a favorable safety and tolerability profile.

• Patients treated with UBX1325 had a mean change from baseline in BCVA of -0.8 ETDRS letters at 24 weeks compared to +3.1 ETDRS letters in the aflibercept control arm.

• Patients treated with UBX1325 had a mean change from baseline in CST of +87.3 µm at 24 weeks compared to +30.5 µm in the aflibercept control arm.

• The company will share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in the second half of 2023.

• Price Action: UBX shares are down 49.2% at $2.11 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.